This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Pharmacologic Treatment of Anxiety Disorders in 1989 Versus 1996: Results From the Harvard/Brown Anxiety Disorders Research Program

Carl Salzman, Idell Goldenberg, Steven E. Bruce, and Martin B. Keller

Published: March 1, 2001

Article Abstract

Objective: This article reports on thepharmacologic treatment of patients diagnosed with generalizedanxiety disorder (GAD) enrolled in a naturalistic long-term studyof anxiety disorders, with enrollment in 1989 through 1991 andfollow-up in 1996.

Method: 711 patients were enrolled in the studyduring 1989-1991. At intake, 167 patients met DSM-III-R criteriafor GAD; at 1996 follow-up, 103 patients met these criteria. Thepatients were divided into 3 groups by diagnosis: GAD alone (N =18 at intake, N = 11 at follow-up), GAD comorbid with anotheranxiety disorder (N = 84 at intake, N = 52 at follow-up), and GADcomorbid with Research Diagnostic Criteria-defined majordepressive disorder, with or without another anxiety disorder (N= 65 at intake, N = 40 at follow-up). The groups were evaluatedat intake and follow-up on whether they received medication andthe types of medication they received.

Results: Nearly one third of patients in the1989-1991 sample were not receiving any medication for treatmentof their anxiety disorder; in 1996, 27% of patients still werereceiving no medication. There was a decrease in benzodiazepinetreatment and an increase in antidepressant treatment in 1996 forGAD patients who did not have comorbid depression or anotheranxiety disorder.

Conclusion: The finding of one quarter to onethird of patients with GAD receiving no medication is consistentwith previous observations of undertreatment of depression. Thefindings on medication type suggest a shift in the type ofmedications being prescribed for treatment of GAD from exclusivebenzodiazepine treatment to the combination of benzodiazepine andantidepressant treatment.

Volume: 62

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF